Dr Tracy Cunningham is the VP, Head of Development at Amryt Pharma, a biopharmaceutical rare and orphan diseases company, since April 2020, with responsibility for pre-clinical and clinical development of the portfolio.
Prior to this, she was in AstraZeneca as Clinical Head, Oncology R&D, leading the clinical development of several new medicines, including the successful registration of Koselugo (selumetinib) for the treatment of paediatric patients with NF1 plexiform neurofibromas. She has over 20 years’ experience in the pharmaceutical industry, predominantly in clinical development and medical affairs.
A 1988 graduate of the Royal College of Surgeons in Ireland and a Fellow of the Royal College of Physicians in Ireland, she specialised in pharmaceutical medicine. She has worked at a senior level in Ireland and Europe, and for the last 10 years at global level in multinational pharmaceutical companies (including Sanofi, GlaxoSmithKline and Novartis) who invest in their respective pipelines of medicines.
She lectures on the Trinity College, Diploma of Pharmaceutical Medicine course on the topic of clinical research. She is a member of the American Society of Clinical Oncology and the American Society of Haematology.